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Dear Editors, 
 
The possibility of human-human transmission of Alzheimer’s disease (AD) has 
never been considered until recently. A landmark study, published in 
September 2015 in Nature, reports the probable seeding of β-amyloid (a 
pathological hallmark of AD) from cadaveric human growth hormone (c-hGH) 
pituitary preparations who also developed iatrogenic Creutzfeldt-Jakob 
Disease (iCJD) from the same source1. Here, we argue that c-hGH was 
historically used to treat rare neuroendocrine disease and that these diseases 
or treatment with GH could result in β-amyloid pathology per se. Without a 
control group of the same patient cohort who neither received c-hGH nor 
developed iCJD, we believe that the authors are premature to infer an 
iatrogenic source of AD. 
 
Cadaveric-hGH was previously used to growth hormone deficiency (GHD) in 
children. In the UK, GH was extracted from a cadaveric pool of approximately 
400,000 pituitary glands and offered as an intramuscular treatment to selected 
patients. Given scarce resources and laborious extraction, its use was 
coordinated in the UK by a Medical Research Council working party in 1959 
that was superseded by the Health Services Human Growth Hormone 
Committee in 19772. In the UK, 1,908 people were registered as having 
received c-hGH from 1959 to 1985 when it was withdrawn worldwide after an 
initial report documenting three deaths from CJD in the US and one in the UK. 
This number rose to 226 incidences worldwide in 20123. From 1985 onwards 
c-hGH became obsolete after being superseded by synthetic recombinant 
forms. 
 
The diverse clinical indications for c-hGH treatment until 1985 are clearly 
presented in a comprehensive epidemiological review which utilised data from 
the Health Services Human Growth Hormone Committee records in the UK4. 
Of the 1908 patients registered as having received c-hGH in the UK, 1004 
(52.6%) had ‘idiopathic’ isolated GHD, 188 (10%) ‘idiopathic’ 
panhypopituitarism, 230 (12.1%) craniopharyngioma, 194 (10.2%) other 
intracranial tumour, 62 (3.3%) other neurological disease e.g. hydrocephalus, 
post meningitis and 62 (3.3%) genetic short stature and growth delay or both 
and 44 (2.3%) Turner’s Syndrome. The remaining causes included Prader-
Willi syndrome, low birth weight, haematological disease, histiocytosis and 
septo-optic dysplasia. These well-recorded historical data demonstrate the 
heterogeneity and severity of neuroendocrine disease necessitating c-hGH 
treatment in the UK prior to 1985. 
 
Supplementary material from the article in question reports the clinical details 
of all 8 patients and the indication for c-hGH treatment, summarized in Table 
1. All patients received c-hGH as children or adolescents and duration of 
treatment was for 2-12 years. From an etiological perspective, 3/8 subjects 
had panhypopituitarism (one also with mental retardation and microcephaly), 
1/8 craniopharyngioma and 4/8 are reported to have been treated for short 
stature alone. This is surprising as short stature alone was an uncommon 
indication for c-hGH prior to 1985, although trials were starting to emerge for 
this indication just prior to the withdrawal of c-hGH5. Short stature should not 
be confused with GHD as the former can be constitutional and the latter is a 
neuroendocrine disease which can lead to short stature. It is therefore likely 
that the ‘short stature’ group disguises a more complicated clinical picture.  
 
At the other end of the clinical spectrum, one of the 4 patients reported as 
having moderate to severe gray matter and vascular β-amyloid pathology had 
a craniopharyngioma. These unusual pituitary tumours can be large, often 
require neurosurgery and/or cranial radiation and are prone to recurrence and 
multiple pituitary hormone deficiencies. Interestingly, the one patient in the 
sporadic CJD control group (aged 65 yrs. approx.) who also had similar levels 
of cerebral amyloid angiopathy (CAA) to the iCJD group was labelled as an 
outlier and it was commented that the subject had a surgical intervention 40 
years before death (Jaunmuktane et al. Extended Data Figures 2&3). 
 
Jaunmuktane and colleagues’ article was preceded by a case series from the 
same research group of the clinical, imaging, molecular and autopsy findings 
of the whole iCJD cohort (n=22)6. One patient had a history of long term 
cognitive problems and additional MRI findings included one patient with 
septo-optic dysplasia and partial agenesis of the corpus callosum. It is not 
clear whether these particular patients were the ones included in the current 
article, but together with the historical records and the supplementary clinical 
details provided, highlight our argument that these patients had complex, rare 
and potentially severe neuroendocrine disease. 
 
With this in mind, an alternative hypothesis contributing to the findings is that 
these pre-existing and underlying conditions could by themselves lead to β-
amyloid pathology and abnormal brain structure. GH is known to have various 
cognitive effects on the brain and isolated GHD in children can lead to lower 
IQ, impaired cognition, reduction brain volumes and white matter 
abnormalities7,8. If GHD continued into adulthood (as it usually does) and was 
untreated then significant cognitive impairments are likely to have persisted 9.  
 
Traumatic brain injury (TBI) we now know is a common cause of GHD in 
children10 and this may not have been widely acknowledged prior to 1985. TBI 
has been associated with widely distributed Aβ deposition in post-mortem 
brain tissue11. Other neurological diseases including epilepsy, fragile X 
syndrome, Down’s syndrome and Parkinson’s disease have all been linked 
with significant increased levels of amyloid precursor protein (APP) and β-
amyloid protein questioning the specificity of this neuropathology to AD. Aβ 
deposition may result from common underlying processes such as 
neuroinflammation, microglial activation and genetic factors12. 
 
The authors comment on the striking CAA in this patient group and 
hypothesize that these individuals ‘would be at increasing risk of cerebral 
haemorrhages had they lived longer’. However, large long-term follow up 
studies of children who received recombinant GH from 1985 onwards (i.e. no 
risk of human-human transmission) were found to have a 5-7 fold increased 
risk of cerebrovascular disease and, in particular, subarachnoid haemorhage, 
suggesting that this cohort have predisposing factors leading to increased risk 
of intracranial haemorrhage, irrespective of having received c-hGH13,14. 
 
In conclusion, the authors present an interesting finding worthy of further 
investigation, but we feel that caution must be exercised in interpreting the 
result, especially in the absence of an appropriate control group. We believe it 
is also important to present a neuroendocrinological perspective and consider 
plausible alternative hypotheses to offer a balanced view on this high profile 
communication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
Patient  Sex History Substantial Aβ 
Focal 
Aβ 
Aβ 
angiopathy 
1 M GH as a child for ~5 years for panhypopituitarism No Yes No 
2 F 
GH as a child for ~10 years for 
panhypopituitarism, mental retardation 
and microcephaly 
No No No 
3 M GH as a child for ~5 years for short stature No Yes No 
4 M GH as a child for short stature from ~7 for ~12 years Yes No Yes 
5 F Craniopharyngioma aged ~10 years, GH from 11 years for ~8 years Yes No No 
6 M GH for short stature from ~9 years for ~5 years Yes No Yes 
7 M GH as an adolescent for ~3 years for panhypopituitarism No No No 
8 M GH for restricted growth from 16 years for ~2 years Yes No Yes 
 
Summary table of the clinical indications for c-hGH treatment in childhood and 
incidence of β-amyloid for each patient (adapted from article text and 
supplementary information) 
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